Follow
Ivan Borbath
Ivan Borbath
Faculté de médecine, Université catholique de Louvain
Verified email at uclouvain.be
Title
Cited by
Cited by
Year
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
147892008
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
E Raymond, L Dahan, JL Raoul, YJ Bang, I Borbath, C Lombard-Bohas, ...
New England Journal of Medicine 364 (6), 501-513, 2011
29152011
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ...
The Lancet Oncology 19 (7), 940-952, 2018
20862018
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib …
P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ...
Jama 315 (17), 1844-1853, 2016
10112016
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...
Journal of Clinical Oncology 36 (3), 276, 2018
6552018
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ...
The lancet oncology 14 (1), 55-63, 2013
6552013
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
JW Valle, I Borbath, SA Khan, F Huguet, T Gruenberger, D Arnold
Annals of Oncology 27, v28-v37, 2016
6472016
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M Heetfeld, CN Chougnet, IH Olsen, A Rinke, I Borbath, G Crespo, ...
Endocrine-related cancer 22 (4), 657-664, 2015
4012015
ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues
RJ Hicks, DJ Kwekkeboom, E Krenning, L Bodei, S Grozinsky-Glasberg, ...
Neuroendocrinology 105 (3), 295-309, 2017
2732017
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
RK Kelley, L Rimassa, AL Cheng, A Kaseb, S Qin, AX Zhu, SL Chan, ...
The Lancet Oncology 23 (8), 995-1008, 2022
2722022
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre …
M Javle, S Roychowdhury, RK Kelley, S Sadeghi, T Macarulla, KH Weiss, ...
The Lancet Gastroenterology & Hepatology 6 (10), 803-815, 2021
2512021
ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology-diagnosis and prognostic stratification
A Perren, A Couvelard, JY Scoazec, F Costa, I Borbath, G Delle Fave, ...
Neuroendocrinology 105 (3), 196-200, 2017
2222017
An update on treatment options for pancreatic adenocarcinoma
A Lambert, L Schwarz, I Borbath, A Henry, JL Van Laethem, D Malka, ...
Therapeutic advances in medical oncology 11, 1758835919875568, 2019
2172019
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or …
P Hammel, F Huguet, JL Van Laethem, D Goldstein, B Glimelius, P Artru, ...
Journal of Clinical Oncology 31 (15_suppl), LBA4003-LBA4003, 2013
202*2013
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S Faivre, P Niccoli, D Castellano, JW Valle, P Hammel, JL Raoul, A Vinik, ...
Annals of oncology 28 (2), 339-343, 2017
1982017
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a …
RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ...
The Lancet 401 (10391), 1853-1865, 2023
1842023
Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
PH Deprez, LMG Moons, D OʼToole, R Gincul, A Seicean, ...
Endoscopy 54 (04), 412-429, 2022
1332022
Pancreatic neuroendocrine tumour grading on endoscopic ultrasound‐guided fine needle aspiration: high reproducibility and inter‐observer agreement of the K i‐67 labelling index
B Weynand, I Borbath, V Bernard, C Sempoux, JF Gigot, C Hubert, ...
Cytopathology 25 (6), 389-395, 2014
1232014
Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction
M Lonneux, I Borbath, A Bol, A Coppens, M Sibomana, R Bausart, ...
European journal of nuclear medicine 26, 591-598, 1999
1181999
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic …
MH Kulke, P Ruszniewski, E Van Cutsem, C Lombard-Bohas, JW Valle, ...
Annals of Oncology 28 (6), 1309-1315, 2017
1132017
The system can't perform the operation now. Try again later.
Articles 1–20